Pfizer And Valneva Announce Primary Vaccination Series Completion In Phase 3 VALOR Lyme Disease Trial; Participants Completed Primary Vaccination Series (3 Doses) With VLA15
Pfizer And Valneva Announce Primary Vaccination Series Completion In Phase 3 VALOR Lyme Disease Trial; Participants Completed Primary Vaccination Series (3 Doses) With VLA15
輝瑞和瓦爾內瓦宣佈VALOR萊姆病三期試驗的主要接種完成；參與者已完成3劑VLA15的主要接種
-
Participants completed primary vaccination series (3 doses) with VLA15
- Primary vaccination series to be followed by a booster approximately one year after completion
- 參與者完成了生物-疫苗VLA15的初級接種計劃（3劑）。
- 初級接種計劃完成後，應在約一年後進行一次加強針。
New York, NY and Saint-Herblain (France), July 17, 2024 – Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN, PARIS:VLA) today announced that the participants of the Phase 3 trial "Vaccine Against Lyme for Outdoor Recreationists" (VALOR) have completed the primary vaccination series (three doses) of Lyme disease vaccine candidate VLA15. Participants will be monitored for the occurrence of Lyme disease cases until the end of the Lyme disease season in 2025.1,
紐交所(PFE)和Valneva SE(納斯達克:VALN，巴黎:VLA)今天宣佈，第三期試驗“針對戶外運動愛好者的萊姆病疫苗”(VALOR)的參與者完成了萊姆病疫苗候選物VLA15的初級接種計劃（三劑）。參與者將在2025年萊姆病季節結束前受監測，以了解萊姆病的發生情況。1